Literature DB >> 29736045

Urosepsis Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli: A Retrospective, Single-Centre Review of Risk Factors and Clinical Outcomes.

Yi-Wenn Yvonne Huang1, Alison Alleyne2, Vivian Leung3, Michael Chapman4.   

Abstract

BACKGROUND: Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae are pathogens that are implicated in urosepsis and may be associated with greater morbidity and mortality than non-ESBL Enterobacteriaceae. Identification of risk factors for ESBL infection may facilitate the selection of appropriate empiric therapy.
OBJECTIVES: The primary objectives were to determine the cumulative incidence of ESBL urosepsis, to identify major risk factors for ESBL urosepsis, and to determine the impact of international travel on development of ESBL urosepsis in an ethnically diverse Canadian population. The secondary objective was to characterize the outcomes of patients with ESBL urosepsis.
METHODS: A single-centre retrospective nested case-control study was conducted from January 2011 to June 2013. The study cohort consisted of adult patients with urosepsis and positive results on blood culture for ESBL-producing and non-ESBL-producing Enterobacteriaceae. Multivariate analysis was then used to determine risk factors for ESBL urosepsis.
RESULTS: The cumulative incidence of ESBL urosepsis at the study site was 19.4% (58/299) over 2.5 years. The 58 cases of ESBL urosepsis were compared with 118 controls (patients with urosepsis caused by non-ESBL Enterobacteriaceae). Significant predictors of ESBL urosepsis were chronic renal insufficiency (odds ratio [OR] 4.66, 95% confidence interval [CI] 1.96-11.08; p < 0.001) and travel to an endemic region in the previous 6 months (OR 4.62, 95% CI 1.17-18.19; p = 0.029), as well as Punjabi or Hindi as the primary language (OR 3.25, 95% CI 1.45-7.29; p = 0.004) and male sex (OR 2.65, 95% CI 1.21-5.80; p = 0.015). Patients with ESBL urosepsis had worse prognosis-in terms of death or discharge with palliative measures only-than those with non-ESBL urosepsis (7/58 [12.1%] versus 4/118 [3.4%]; p = 0.042).
CONCLUSIONS: Institution-specific data support prompt recognition of patients at risk for ESBL infections. Chronic renal insufficiency, recent travel to regions endemic for ESBL-producing organisms, primary language of Punjabi or Hindi, and male sex were the strongest risk factors for ESBL urosepsis at the study centre. However, findings from this single-centre study may not be generalizable to other institutions.

Entities:  

Keywords:  extended-spectrum β-lactamase urosepsis; risk factors; travel

Year:  2018        PMID: 29736045      PMCID: PMC5931071     

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN: 0008-4123


  33 in total

Review 1.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

2.  Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.

Authors:  Mitchell J Schwaber; Yehuda Carmeli
Journal:  J Antimicrob Chemother       Date:  2007-09-11       Impact factor: 5.790

3.  International travel is a risk factor for extended-spectrum β-lactamase-producing Enterobacteriaceae acquisition in children: A case-case-control study in an urban U.S. hospital.

Authors:  Jonathan P Strysko; Vidya Mony; Jeremiah Cleveland; Hanna Siddiqui; Peter Homel; Christina Gagliardo
Journal:  Travel Med Infect Dis       Date:  2016-11-24       Impact factor: 6.211

4.  Costs and length of stay associated with extended-spectrum β-lactamase production in cases of Escherichia coli bloodstream infection.

Authors:  Rasmus Leistner; Andy Bloch; Christian Sakellariou; Petra Gastmeier; Frank Schwab
Journal:  J Glob Antimicrob Resist       Date:  2014-02-12       Impact factor: 4.035

5.  Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria.

Authors:  L S Briongos-Figuero; T Gómez-Traveso; P Bachiller-Luque; M Domínguez-Gil González; A Gómez-Nieto; T Palacios-Martín; M González-Sagrado; A Dueñas-Laita; J L Pérez-Castrillón
Journal:  Int J Clin Pract       Date:  2012-09       Impact factor: 2.503

Review 6.  The epidemiology of urinary tract infection.

Authors:  Betsy Foxman
Journal:  Nat Rev Urol       Date:  2010-12       Impact factor: 14.432

7.  Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study.

Authors:  James A Karlowsky; Philippe R S Lagacé-Wiens; Patricia J Simner; Melanie R DeCorby; Heather J Adam; Andrew Walkty; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

Review 8.  Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M.

Authors:  Paul-Louis Woerther; Charles Burdet; Elisabeth Chachaty; Antoine Andremont
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 9.  Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis.

Authors:  Konstantinos Z Vardakas; Giannoula S Tansarli; Petros I Rafailidis; Matthew E Falagas
Journal:  J Antimicrob Chemother       Date:  2012-08-21       Impact factor: 5.790

10.  New Delhi metallo-beta-lactamase from traveler returning to Canada.

Authors:  Gisele Peirano; Jasmine Ahmed-Bentley; Neil Woodford; Johann D Pitout
Journal:  Emerg Infect Dis       Date:  2011-02       Impact factor: 6.883

View more
  5 in total

1.  Short- and long-term mortality in patients with urosepsis caused by Escherichia coli susceptible and resistant to 3rd generation cephalosporins.

Authors:  Milena Tocut; Iris Zohar; Orna Schwartz; Orit Yossepowitch; Yasmin Maor
Journal:  BMC Infect Dis       Date:  2022-06-24       Impact factor: 3.667

Review 2.  Evaluation of the health and healthcare system burden due to antimicrobial-resistant Escherichia coli infections in humans: a systematic review and meta-analysis.

Authors:  M C MacKinnon; J M Sargeant; D L Pearl; R J Reid-Smith; C A Carson; E J Parmley; S A McEwen
Journal:  Antimicrob Resist Infect Control       Date:  2020-12-10       Impact factor: 4.887

3.  Clinical characteristics and prognosis in patients with urosepsis from intensive care unit in Shanghai, China: a retrospective bi-centre study.

Authors:  Ying Sheng; Wen-Long Zheng; Qi-Fang Shi; Bing-Yu Zhang; Guang-Yao Yang
Journal:  BMC Anesthesiol       Date:  2021-11-27       Impact factor: 2.217

4.  Variation of effect estimates in the analysis of mortality and length of hospital stay in patients with infections caused by bacteria-producing extended-spectrum beta-lactamases: a systematic review and meta-analysis.

Authors:  Parichehr Shamsrizi; Beryl Primrose Gladstone; Elena Carrara; Dora Luise; Andrea Cona; Chiara Bovo; Evelina Tacconelli
Journal:  BMJ Open       Date:  2020-01-20       Impact factor: 2.692

5.  Retrospective Study of the Etiology, Laboratory Findings, and Management of Patients with Urinary Tract Infections and Urosepsis from a Urology Center in Silesia, Southern Poland Between 2017 and 2020.

Authors:  Zygmunt F Gofron; Malgorzata Aptekorz; Katarzyna W Gibas; Monika Kabała; Gayane Martirosian
Journal:  Med Sci Monit       Date:  2022-03-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.